一是增强理性投资意识。谨记"天上不会掉馅饼，高利保本是陷阱"，对"高额回报""快速致富"等投资项 目冷静分析，对高额返利不动心、对宣传炒作不盲信、对熟人介绍不盲从，避免上当受骗。 二是认清非法集资本质。在投资前，要充分了解项目的真实性、合法性以及潜在风险，切勿盲目跟风、 追随热点，理性看待"区块链、元宇宙、云养殖"等新概念，不要被各类花样翻新的非法金融形式迷惑。 随着元宇宙概念大火，一些不法分子花式蹭热点，打着元宇宙区块链旗号，翻炒与元宇宙相关的游戏制 作、虚拟现实等概念，或宣称"边玩游戏边赚钱"，诱骗公众通过兑换虚拟币、购买游戏装备等方式投 资，或编织包装名目众多的高科技投资项目，公开虚假宣传高额收益，吸收公众资金，具有非法集资、 诈骗等违法行为特征。 【以"云养"之名，行"非法"之实】 一些不法分子以"农业+科技"为噱头，打着"云养牛""云种植"等发展农业产业的幌子，将正常的农产品 种养、销售包装为投资融资活动。通过AI技术伪造养殖、种植的视频图片，虚构或夸大实际生产场 景，以种养收益分红、农特产品返还等为诱饵，吸引公众投入资金，不断扩充资金池，涉嫌非法集资、 传销等多种犯罪行为。 非法金融虽形式多变、场 ...

截至3月12日收盘，EDR概念上涨2.73%，位居概念板块涨幅第1，板块内，17股上涨，锐明技术、得润 电子等涨停，鸿泉物联、天融信、启明信息等涨幅居前，分别上涨14.26%、2.83%、2.54%。跌幅居前 的有国民技术、江波龙等，分别下跌1.12%、0.68%。 资金流入比率方面，得润电子、锐明技术、东风科技等流入比率居前，主力资金净流入率分别为 36.87%、26.28%、6.70%。（数据宝） EDR概念资金流入榜 今日涨跌幅居前的概念板块 资金面上看，今日EDR概念板块获主力资金净流入4.37亿元，其中，14股获主力资金净流入，6股主力 资金净流入超3000万元，净流入资金居首的是得润电子，今日主力资金净流入1.79亿元，净流入资金居 前的还有锐明技术、全志科技、均胜电子等，主力资金分别净流入1.30亿元、9067.23万元、5441.76万 元。 ...

资金面上看，今日重组蛋白概念板块获主力资金净流出1.61亿元，其中，26股获主力资金净流出，7股 主力资金净流出超千万元，净流出资金居首的是江苏吴中，今日主力资金净流出5028.11万元，净流出 资金居前的还有一品红、智飞生物、神州细胞等，主力资金分别净流出2905.64万元、2141.55万元、 2129.05万元。今日主力资金净流入居前的概念股有博瑞医药、健友股份、凯因科技等，主力资金分别 净流入2788.63万元、1436.39万元、966.66万元。（数据宝） 重组蛋白概念资金流出榜 今日涨跌幅居前的概念板块 截至3月12日收盘，重组蛋白概念下跌1.04%，位居概念板块跌幅榜前列，板块内，热景生物、科兴制 药、泽璟制药等跌幅居前，股价上涨的有7只，涨幅居前的有丸美生物、健友股份、百普赛斯等，分别 上涨2.93%、2.39%、0.77%。 ...

Bank of England Point-of-sale proof of concept Digital pound experiment report May 2024 Bank of England Page 1 Contents | Summary | 2 | | --- | --- | | Background | 3 | | Project overview | 6 | | Results | 19 | | Reflection and next steps | 2 0 | Bank of England Summary As part of the design phase for a digital pound, the Bank of England (the Bank) is conducting experiments and proofs of concept (PoC) in collaboration with private-sector innovators and a range of stakeholders. These aim to assess the techni ...

盘面上，数据中心电源概念走强，科泰电源20%涨停，潍柴重机、泰豪科技等涨停；影视传媒板块活 跃，华数传媒、金逸影视涨停。 人民财讯3月12日电，3月12日，三大指数早间窄幅震荡，截至午间收盘，沪指跌0.14%，深证成指涨 0.02%，创业板指跌0.24%。 此外，游戏、通信服务、电网设备、汽车零部件、消费电子、国资云、东数西算概念等板块涨幅居前； 能源金属、航空机场、医疗器械、酿酒、工程机械、猪肉、乳业概念等板块跌幅居前。 全市场超2800只个股上涨。 ...

AUBURN HILLS, Mich., March 10, 2025 /PRNewswire/ -- Mopar’s annual factory-vehicle customization program delivers an exclusive package for the Mopar '25 Ram 1500 RHO, featuring exclusive interior and exterior content. Production is limited to 250 units (225 for the U.S. and 25 for Canada). Mopar's annual factory-vehicle customization program delivers an exclusive package for the 2025 Ram 1500 RHO   Mopar '25 Package features special interior and exterior content inspired by the 'Moparized' Ram 1500 RH ...

Positioning asset to become an 18-hour activity hub that better serves the lifestyle needs of the surrounding community Meets neighborhood demand for an upscale coffeehouse, premium fitness concepts and executive suites by bringing in Starbucks Reserve, Pvolve, RVE Fitness and CUBExec HOUSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Whitestone REIT (NYSE:WSR), a neighborhood-focused owner and operator of open-air shopping centers in Texas and Arizona, today announced that it has commenced a strategic transformat ...

Investment Rating - The industry investment rating is "Positive" (maintained) [5] Core Insights - The smart AR glasses market is expected to evolve significantly, driven by products like Ray-Ban Meta, potentially leading to a breakthrough year in 2025 [5] - The optical waveguide display function remains a key technical focus, with silicon carbide (SiC) anticipated to play a crucial role in optimizing optical pathways [5] - The adoption of high-refractive-index materials, particularly silicon carbide, is essential for achieving total internal reflection in optical waveguide designs [3][4] Summary by Sections Optical Waveguide Display Solutions - The main optical display solutions currently rely on waveguide technology, which can be categorized into reflection and diffraction routes [2] - Reflection waveguides utilize micro-mirror arrays on lens surfaces to achieve imaging through total internal reflection, while diffraction waveguides adjust light paths via etched or nano-imprinted gratings [2] Silicon Carbide as a Key Material - Silicon carbide, with a refractive index of 2.7, significantly reduces the critical angle for total internal reflection compared to traditional glass, which has a refractive index of about 1.8 [3] - The use of silicon carbide allows for thinner lenses and minimizes light interference effects, making it a strong candidate for future smart glasses [3] Market Dynamics and Opportunities - The current production capacity for consumer-grade silicon carbide is limited, presenting a high barrier to entry, which could benefit companies with core technological capabilities [4] - Tianyue Advanced, a leading domestic silicon carbide substrate company, is highlighted as a key player in this emerging market [4]

Core Insights - Oruka Therapeutics is advancing its clinical pipeline with ORKA-001 and ORKA-002, targeting chronic skin diseases like plaque psoriasis, with significant clinical data expected in the coming years [1][2][3] Financial Overview - The company successfully raised over $475 million in 2024, providing a cash runway through 2027, which is over one year past the anticipated Phase 2a data for ORKA-001 [1][12] - As of December 31, 2024, Oruka had cash, cash equivalents, and marketable securities totaling approximately $394 million [7] - The net loss for the fourth quarter of 2024 was $25.8 million, with a total net loss of $83.7 million since inception [11][18] Research and Development Updates - ORKA-001, a novel IL-23p19 monoclonal antibody, is currently in a Phase 1 trial, with interim pharmacokinetic data expected in the second half of 2025 [1][5] - A Phase 2a proof-of-concept study for ORKA-001 is planned for the second half of 2025, aiming to enroll around 80 patients with moderate-to-severe psoriasis [5] - ORKA-002, targeting IL-17A/F, is set to enter Phase 1 trials in Q3 2025, with preclinical data to be presented at the 2025 AAD Annual Meeting [1][12] Clinical Development Strategy - The company aims to deliver clinical catalysts every six months, potentially establishing ORKA-001 and ORKA-002 as leading treatment options in psoriatic disease [2] - ORKA-001 has shown a half-life in non-human primates exceeding 30 days, suggesting the potential for extended dosing intervals [5] - The innovative study design for ORKA-001 includes a primary endpoint of PASI 100 at week 16, which is more stringent than previous studies [5] Additional Programs - Oruka is developing ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001, which could enhance treatment responses [12] - The company plans to disclose further details on ORKA-003 in the first half of 2025 [12]

截至发稿，广发中证医疗ETF跌1.49%，华宝中证医疗ETF跌1.43%，国泰中证医疗ETF跌1.39%，华夏 中证全指医疗器械ETF跌1.38%，华泰柏瑞中证全指医疗保健设备与服务ETF跌1.35%。 人民财讯3月5日电，AI医疗概念回调，多只ETF跌超1%。 ...